Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy
Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy
About this item
Full title
Author / Creator
Zhao, Binghao , Li, Huanzhang , Xia, Yu , Wang, Yaning , Wang, Yuekun , Shi, Yixin , Xing, Hao , Qu, Tian , Wang, Yu and Ma, Wenbin
Publisher
London: BioMed Central
Journal title
Language
English
Formats
Publication information
Publisher
London: BioMed Central
Subjects
More information
Scope and Contents
Contents
Immunotherapy for cancer is a rapidly developing treatment that modifies the immune system and enhances the antitumor immune response. B7-H3 (CD276), a member of the B7 family that plays an immunoregulatory role in the T cell response, has been highlighted as a novel potential target for cancer immunotherapy. B7-H3 has been shown to play an inhibit...
Alternative Titles
Full title
Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_70bc0c98887748f3883dd05913373de4
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_70bc0c98887748f3883dd05913373de4
Other Identifiers
ISSN
1756-8722
E-ISSN
1756-8722
DOI
10.1186/s13045-022-01364-7
